Wednesday, July 15, 2026

pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)

Amgen

Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec

One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
One Amgen Center Drive, Thousand Oaks, CA 91320, US
Founded
1980
Employees
40,212
Programs
2
Drugs
86
Patents
1
Clinical program

Dexamethasone

Phase 3 · small molecule · Relapsed Multiple Myeloma

Dexamethasone for Relapsed Multiple Myeloma is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).

← All Amgen projects Phase 3 small molecule completed

Internal code 20160275

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Amgen
Phase
Phase 3
Modality
small_molecule
Indication
Relapsed Multiple Myeloma
Status
completed
Trials
1